Perrigo's Mixed Q1 2026: Innovation & Cost Cuts

Perrigos Q1 2026 earnings show a mixed bag amidst market challenges. Core net sales dropped 8.3%, but adjusted EPS beat expectations due to tariff recoveries and cost cuts. The Three-S plan is yielding results, with U.S. store-brand OTC volume share up 270 basis points. They sold Dermacosmetics for debt reduction and saved over $7 million on efficiency. Despite market headwinds, Perrigo gained share in nicotine therapy, allergy, and pain. Looking ahead, theyre banking on innovation and lapping last years production issues for a second-half lift. Ongoing reviews may lead to more streamlining, and theyre managing inflation from Middle East tensions. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/434ad67598da1d19